Clinical Trials Logo

Cholangiocarcinoma clinical trials

View clinical trials related to Cholangiocarcinoma.

Filter by:

NCT ID: NCT03527875 Not yet recruiting - Clinical trials for Jaundice, Obstructive

Process Optimization of Preoperative Biliary Drainage in Hilar Cholangiocarcinoma Patients

Start date: August 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of different methods of preoperative biliary drainage in hilar cholangiocarcinoma patients, including PTBD (Percutaneous Transhepatic Biliary Drainage), ENBD (Endoscopic Nasobiliary Drainage) and EBS (Endoscopic Biliary Stenting).

NCT ID: NCT03525067 Completed - Pancreatic Cancer Clinical Trials

Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies

Start date: February 1, 2017
Phase:
Study type: Observational

The aim of the present prospective study was, first, to verify the correlation between biliary colonization and postoperative infectious complications, and secondarily to asses morbidity and mortality for patients who underwent pancreaticoduodenectomy. The hypothesis is that a proportion of post-operative infections after pancreaticoduodenectomy is due to bacteria that colonize the bile ducts during the preoperative period.

NCT ID: NCT03521219 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Start date: February 7, 2018
Phase: Phase 2
Study type: Interventional

The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.

NCT ID: NCT03499782 Recruiting - Cholangiocarcinoma Clinical Trials

Precise Treatment System of Biliary Malignancies Based on Special Disease Database

Start date: May 25, 2018
Phase:
Study type: Observational

Malignant tumors of biliary system lack standard treatment and precise prognosis assessment methods. This study including 12 hospitals, collecting clinical and follow-up data of patients with biliary malignant tumors including cholangiocarcinoma and gallbladder carcinoma in recent 10 years, aim to build a special disease database, then use Bayesian networks and importance theory to establish a mathematical model to assess treatment strategies and prognosis accurately. At the same time, data on biliary malignant tumors newly treated by multicenters from 2018 to 2020 will be included to validate, adjust and refine the models to guide clinical individualized precise treatment.

NCT ID: NCT03494023 Recruiting - Pancreatic Cancer Clinical Trials

EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice

ECCO
Start date: March 27, 2018
Phase:
Study type: Observational

The main objective of the study is to evaluate the size of the common bile duct (CBD) in a large cohort of patients with jaundice secondary to pancreatic head or distal bile duct malignancy undergoing diagnostic EUS for tissue acquisition or evaluation of resectability and to establish factors associated with a dilation of the CBD greater than 15mm.

NCT ID: NCT03486678 Recruiting - Cholangiocarcinoma Clinical Trials

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Start date: February 10, 2018
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label and exploratory clinical study of PD-1 monoclonal antibody SHR-1210 combined with GEMOX regimen (gemcitabine combined oxaliplatin) in the treatment of advanced biliary malignancies. In oder to observe and evaluate the efficacy and safety of PD-1 antibody SHR-1210 combined with GEMOX in the treatment of patients with advanced biliary malignant tumor (BTC),subjects with pathological confirmed biliary cancer, including intrahepatic bile duct carcinoma, extrahepatic bile duct carcinoma, and gallbladder carcinoma will be enrolled. 28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy will be used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond 6 cycles chemotherapy until disease progression or un-tolerable toxicity.

NCT ID: NCT03475966 Recruiting - Pancreatic Cancer Clinical Trials

Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program

Start date: February 22, 2017
Phase: N/A
Study type: Interventional

Major surgery is a stressful procedure; good recovery after surgery is important to patients and their doctors. Studies done at the McGill University Health Centre (MUHC) with cancer patients awaiting surgery have shown that exercise combined with simple diet recommendations (which may include a supplement) and relaxation techniques before surgery helped speed up the ability to resume walking after surgery. These results have made the investigators aware that exercise and good nutrition are as important before surgery as they are after surgery; while it is common practice to start strengthening the body after surgery (rehabilitation), there may be some advantage to begin this process before surgery (prehabilitation). The purpose of this study is to see if the following program, either before or after surgery, can help patients recover from liver, pancreas or bile duct surgery: 1. Exercise that may help participants move and breath better, 2. Nutrition advice and a supplement to make participants strong, 3. Relaxation and anti-anxiety tips to help cope with the stress of upcoming surgery The investigators will see if following this program will have an effect on participants' ability to walk before and after surgery.

NCT ID: NCT03473574 Not yet recruiting - Cholangiocarcinoma Clinical Trials

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

IMMUCHEC
Start date: March 2018
Phase: Phase 2
Study type: Interventional

To determine the efficacy in terms of objective response rate (ORR) of the combination of durvalumab and tremelimumab in addition with gemcitabine or in addition with gemcitabine and cisplatin in treatment-naïve patients with advanced, unresectable and/or metastatic cholangio- and gallbladder carcinoma (CCA).

NCT ID: NCT03452774 Recruiting - Breast Cancer Clinical Trials

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Start date: January 1, 2018
Phase: N/A
Study type: Observational [Patient Registry]

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

NCT ID: NCT03447691 Recruiting - Clinical trials for Pancreatic Cancer or Distal CBD Cancer

Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery

Start date: August 27, 2017
Phase: N/A
Study type: Interventional

Investigators asses whether there is any difference in short term recovery and long term prognosis according to the anesthetic method in patients who undergoing pancreatic cancer and bile duct cancer and undergoing surgery for PPPD or distal pancreatectomy.